Dunham Eric C, Banadyga Logan, Groseth Allison, Chiramel Abhilash I, Best Sonja M, Ebihara Hideki, Feldmann Heinz, Hoenen Thomas
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 903 South 4th Street, Hamilton, Montana 59840, USA.
Nat Commun. 2015 Aug 5;6:8000. doi: 10.1038/ncomms9000.
The current Ebola virus (EBOV) outbreak in West Africa is unprecedented in terms of both its size and duration, and there has been speculation and concern regarding the potential for EBOV to increase in virulence as a result of its prolonged circulation in humans. Here we investigate the relative potency of the interferon (IFN) inhibitors encoded by EBOVs from West Africa, since an important EBOV virulence factor is inhibition of the antiviral IFN response. Based on this work we show that, in terms of IFN antagonism, the West African viruses display no discernible differences from the prototype Mayinga isolate, which corroborates epidemiological data suggesting these viruses show no increased virulence compared with those from previous outbreaks. This finding has important implications for public health decisions, since it does not provide experimental support for theoretical claims that EBOV might gain increased virulence due to the extensive human-to-human transmission in the on-going outbreak.
当前在西非爆发的埃博拉病毒（EBOV）疫情，无论是规模还是持续时间都史无前例。有人猜测并担心，由于EBOV在人类中长时间传播，其毒力可能会增强。在此，我们研究了来自西非的EBOV编码的干扰素（IFN）抑制剂的相对效力，因为EBOV的一个重要毒力因子是对抗病毒IFN反应的抑制。基于这项工作，我们表明，在IFN拮抗作用方面，西非病毒与原型Mayinga毒株没有明显差异，这与流行病学数据相佐证，表明这些病毒与之前疫情中的病毒相比，毒力并未增加。这一发现对公共卫生决策具有重要意义，因为它没有为关于EBOV可能因当前疫情中广泛的人际传播而增加毒力的理论主张提供实验支持。
Zotero 插件
